We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Routine Blood Glucose Value Correlates with Diabetes Risk

By LabMedica International staff writers
Posted on 22 Mar 2015
Print article
Image: UniCel DxC 800 Synchron Clinical Systems (Photo courtesy of Beckman Coulter).
Image: UniCel DxC 800 Synchron Clinical Systems (Photo courtesy of Beckman Coulter).
Random glucose values obtained during routine blood tests are often overlooked, but could provide valuable insight into whether someone is at risk for having type 2 diabetes.

Random Blood Glucose (RBG) values in which the clinician is unaware of when the patient last ate account for the majority of glucose tests in clinical practice. Current guidelines do not call for using RBG values as a screening test for diabetes and do not consider higher levels an indicator of diabetes risk.

Scientists at the University of Texas Southwestern Medical Center (Dallas, TX, USA) analyzed data from 13,792 participants in the 2005-2010 National Health and Nutrition Examination Surveys, which tested participants for diabetes as part of the survey. The investigators examined the association between random blood glucose and a patient's diabetes status in patients without diagnosed diabetes. The study population consisted of non-pregnant adults, age18 and older.

Serum RBG measurements were determined using the Beckman Oxygen electrode, glucose oxidase method. Between 2007and 2012, one instrument change occurred as from 2008 the Beckman Unicel CxC800 Synchron (Beckman Coulter; Brea, CA, USA) was used. HbA1C assays were conducted using high-performance liquid chromatography (HPLC) methods mainly on the Tosoh HbA1C G7 (Tosoh Bioscience, Inc.; South San Francisco, CA, USA). Diabetes was defined as having an HbA1C ≥ 6.5% (48 mmol/mol) and prediabetes as having an HbA1C of 5.7–6.4% (39–46mmol/mol). Dysglycemia was defined as having an HbA1C ≥ 5.7% (39 mmol/mol).

The team found that those with even modest elevations in random blood glucose (RBG), between 100 to 119 mg/dL, were seven-times more likely to have diabetes, according to the study. As that number rose, so did the risk. Those with RBG values of 120 to 139 mg/dL were 30-times as likely to have undiagnosed diabetes. Individuals with values under 100 mg/dL served as a reference point and were not considered at risk.

Michael E. Bowen, MD, MPH, an assistant professor of Internal Medicine and lead author, said, “Our results provide compelling evidence that a single, elevated random blood glucose value is a strong risk factor for diabetes. After adjusting for traditional diabetes risk factors, we found that individuals with a single random glucose value greater than or equal to 100 mg/dL were 20-times more likely to have undiagnosed diabetes compared with those whose values were less than 100 mg/dL. We shouldn't ignore these values. If we do, we are missing an opportunity to identify patients at high risk for diabetes.” The study was published on February 4, 2015, in the Journal of Clinical Endocrinology and Metabolism.

Related Links:
University of Texas Southwestern Medical Center
Beckman Coulter 
Tosoh Bioscience 



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Aspergillus Test
REALQUALITY Aspergillus
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.